Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LSB NASDAQ:MNOV NASDAQ:OTLK NASDAQ:RPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLSBLakeShore Biopharma$0.78-1.3%$0.97$0.59▼$8.60$16.20M0.56132,588 shs27,444 shsMNOVMediciNova$1.31+0.8%$1.31$1.13▼$2.55$62.29M0.3521,370 shs24,831 shsOTLKOncobiologics$2.34-3.7%$1.93$0.87▼$8.32$78.55M0.26730,457 shs2.65 million shsRPTXRepare Therapeutics$1.57+0.6%$1.48$0.89▼$4.07$67.45M0.93312,720 shs36,882 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLSBLakeShore Biopharma+3.15%+16.86%-25.47%-30.70%-82.05%MNOVMediciNova+2.36%-5.11%+5.69%-1.52%+15.04%OTLKOncobiologics+14.08%+32.07%+7.05%+38.86%-66.89%RPTXRepare Therapeutics-1.89%+2.63%+9.09%+16.42%-44.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLSBLakeShore Biopharma1.4951 of 5 stars0.05.00.00.02.90.80.6MNOVMediciNova2.4683 of 5 stars3.83.00.00.02.70.80.0OTLKOncobiologics1.8035 of 5 stars3.42.00.00.02.10.00.6RPTXRepare Therapeutics2.8077 of 5 stars3.33.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLSBLakeShore Biopharma 0.00N/AN/AN/AMNOVMediciNova 3.50Strong Buy$7.00434.35% UpsideOTLKOncobiologics 2.80Moderate Buy$9.60310.26% UpsideRPTXRepare Therapeutics 2.50Moderate Buy$4.50186.62% UpsideCurrent Analyst Ratings BreakdownLatest LSB, RPTX, OTLK, and MNOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025OTLKOncobiologicsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.007/24/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/16/2025MNOVMediciNovaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.006/6/2025OTLKOncobiologicsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $21.005/20/2025OTLKOncobiologicsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLSBLakeShore Biopharma$85.67M0.19N/AN/A$3.35 per share0.23MNOVMediciNova$1MN/AN/AN/A$1.07 per shareN/AOTLKOncobiologicsN/AN/AN/AN/A($3.09) per shareN/ARPTXRepare Therapeutics$53.48M1.26N/AN/A$2.57 per share0.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLSBLakeShore Biopharma-$13.93MN/A0.00∞N/AN/AN/AN/A8/21/2025 (Estimated)MNOVMediciNova-$11.04M-$0.23N/AN/AN/AN/A-20.77%-19.68%N/AOTLKOncobiologics-$75.37M-$0.91N/AN/AN/AN/AN/A-271.12%N/ARPTXRepare Therapeutics-$84.69M-$2.58N/AN/AN/AN/A-78.25%-66.85%N/ALatest LSB, RPTX, OTLK, and MNOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MNOVMediciNova-$0.07-$0.07N/A-$0.07N/A$0.14 million8/14/2025Q3 2025OTLKOncobiologics-$0.42-$0.44-$0.02-$0.55$1.66 million$1.51 million8/8/2025Q2 2025RPTXRepare Therapeutics-$0.56-$0.39+$0.17-$0.39$2.50 million$0.25 million5/15/2025Q2 2025OTLKOncobiologics-$0.55-$0.40+$0.15-$1.50$0.70 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLSBLakeShore BiopharmaN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/ARPTXRepare TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLSBLakeShore Biopharma0.051.020.75MNOVMediciNovaN/A17.6617.66OTLKOncobiologicsN/A0.720.57RPTXRepare TherapeuticsN/A6.307.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLSBLakeShore Biopharma52.64%MNOVMediciNova9.90%OTLKOncobiologics11.20%RPTXRepare Therapeutics85.09%Insider OwnershipCompanyInsider OwnershipLSBLakeShore BiopharmaN/AMNOVMediciNova13.60%OTLKOncobiologics4.80%RPTXRepare Therapeutics11.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLSBLakeShore Biopharma77320.77 millionN/AN/AMNOVMediciNova10N/AN/AOptionableOTLKOncobiologics2033.57 million31.96 millionOptionableRPTXRepare Therapeutics18042.96 million38.02 millionOptionableLSB, RPTX, OTLK, and MNOV HeadlinesRecent News About These CompaniesRepare Therapeutics Announces Licensing Deal and Strategic UpdatesAugust 12 at 10:25 PM | theglobeandmail.comRepare Therapeutics (NASDAQ:RPTX) Posts Earnings ResultsAugust 11, 2025 | marketbeat.comRepare Therapeutics (NASDAQ:RPTX) Upgraded by Wall Street Zen to Hold RatingAugust 11, 2025 | americanbankingnews.comRepare Therapeutics (NASDAQ:RPTX) Stock Rating Upgraded by Wall Street ZenAugust 10, 2025 | marketbeat.comRepare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue EstimatesAugust 8, 2025 | zacks.comRepare (RPTX) Q2 Loss Narrows 52%August 8, 2025 | fool.comRepare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 8, 2025 | financialpost.comFRepare Therapeutics (RPTX) to Release Quarterly Earnings on TuesdayJuly 30, 2025 | marketbeat.comARK Investment Management LLC Sells 875,514 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX)July 27, 2025 | marketbeat.comRepare Therapeutics (NASDAQ:RPTX) Trading 0.6% Higher - What's Next?July 26, 2025 | marketbeat.comRepare Therapeutics Jumps 15% After $10M Licensing Deal With DebiopharmJuly 18, 2025 | uk.finance.yahoo.comRepare Therapeutics Inc. (RPTX) - Yahoo FinanceJuly 17, 2025 | finance.yahoo.comRepare inks licensing deal with Debiopharm for lunresertibJuly 16, 2025 | thepharmaletter.comTRepare finds suitor for paused PKMYT1 inhibitor in current partner DebiopharmJuly 16, 2025 | fiercebiotech.comFRepare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush InJuly 16, 2025 | msn.comRepare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for LunresertibJuly 15, 2025 | financialpost.comFRepare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for LunresertibJuly 15, 2025 | financialpost.comFRepare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for LunresertibJuly 15, 2025 | businesswire.comRepare Therapeutics Inc (RPTX) - Investing.comJuly 3, 2025 | investing.comRepare Therapeutics Inc (RPTX) Stock Forums - Investing.comJune 30, 2025 | investing.comRepare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic DealJune 25, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLSB, RPTX, OTLK, and MNOV Company DescriptionsLakeShore Biopharma NASDAQ:LSB$0.78 -0.01 (-1.27%) As of 03:59 PM EasternLakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.MediciNova NASDAQ:MNOV$1.31 +0.01 (+0.77%) Closing price 04:00 PM EasternExtended Trading$1.38 +0.07 (+5.65%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.Oncobiologics NASDAQ:OTLK$2.34 -0.09 (-3.70%) Closing price 04:00 PM EasternExtended Trading$2.39 +0.05 (+2.09%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Repare Therapeutics NASDAQ:RPTX$1.57 +0.01 (+0.64%) Closing price 04:00 PM EasternExtended Trading$1.57 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH Deere’s Sell-Off Could Be a Long-Term Buying Chance Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Arista Networks: Cashing In as the Tollbooth for AI Traffic Green Dot's 30% Rally: Turnaround Takes Off on Explosive Earnings How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access